Presbia PLC is an Ireland-based medical device company specializing in innovative ophthalmic solutions for presbyopia, the age-related loss of near vision. The company’s lead product, the Presbia Flexivue Microlens, is a precisely engineered corneal inlay designed to be implanted into the corneal stroma. By creating a small permanent refractive change, the lens restores near vision while preserving distance visual acuity through a minimally invasive procedure.
Founded in 2006 and headquartered in Dublin, Presbia earned CE mark approval for the Flexivue Microlens in the European Union and commenced commercial sales in select EU markets shortly thereafter. The company has since forged distribution agreements to introduce its technology in Latin America and parts of Asia, working with local partners to expand patient access and surgeon training in its presbyopia treatment.
In the United States, Presbia is advancing its clinical program under an investigational device exemption (IDE) to assess safety and efficacy for potential FDA approval. Ongoing research and development efforts focus on refining the surgical delivery system, optimizing lens materials, and broadening patient eligibility criteria to enhance visual outcomes and procedural efficiency.
Presbia’s management team combines expertise in medical device development, regulatory affairs and ophthalmic surgery. The company supports its commercial efforts with robust training and educational initiatives for eye-care professionals, aiming to drive adoption of its reversible presbyopia solution and meet the global demand for age-related vision correction.
AI Generated. May Contain Errors.
Free LENSF Stock Alerts